Synthetic Biologics - TOVX Net earnings per share for the last four quarters

Official company branding of Synthetic Biologics (TOVX)

The TTM YoY earnings per share metric on GURU.Markets demonstrates profitability trends, where the value 95.80 describes the current level. The biopharmaceutical sector remains stable, yet dependent on sanctions and patent disputes. Theriva Biologics, Inc. (TOVX) develops oncolytic viruses to combat tumor recurrences. Meanwhile, the company's environmental footprint is minimal due to the specific nature of laboratory testing.

Theriva Biologics (TOVX) Earnings per share for the last twelve months: for the period 02/11/2024 - 11/18/2026

TOVX (Theriva Biologics): analytical breakdowns and indicator data

Initial company analysis:TOVX, Synthetic Biologics
Mass-produced product of therivabio.com

Theriva Biologics, Inc. (TOVX) specializes in the development of oncology drugs and is currently in the clinical trial stage. This metric captures the percentage change in net income per share over the last twelve months relative to the previous year. This indicator reflects the business's ability to withstand inflationary costs and rising resource prices. Ignoring macroeconomics turns the search for growth assets into a dangerous illusion. By analyzing the YoY ttm earnings per share trend, an investor can see the real efficiency of capital management.

Direct competitors

Earnings per share for the trailing year IBRX (ImmunityBio)|IMCR: Net earnings per share (EPS TTM)|JANX - Net earnings per share for the last four quarters|Earnings per share for the last twelve months arcusbio.com|Net earnings per share for the last 12 months zymeworks.com (ZYME)|Earnings per share for the last twelve months Tango Therapeutics Inc (TNGX)|Net earnings per share for the last 12 months Iovance IOVA|Immatics NV - Net earnings per share for the last 12 months|Net earnings per share (EPS TTM) Xencor Inc. XNCR|CMPX - Earnings per share for the last twelve months|REPL (replimune.com) - Earnings per share for the last 12 months|Lyell Pharma (LYEL) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Innate Pharma, S.A. (IPHA)|Net earnings per share for the last 12 months PYXS|CGEN - Net earnings per share for the trailing year|Net earnings per share for the last 12 months IOBT (IO Biotech Corp)|Earnings per share for the last four quarters STRO|Net earnings per share (EPS TTM) INKT (MiNK Therapeutics)|Earnings per share for the trailing year HOWL|Immix - Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months ALX Oncology Holdings Inc.|CUE: Net earnings per share (EPS TTM)|PDS Biotech - Earnings per share for the trailing year|SONN (Sonnet BioTherapeutics Holdings Inc.) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) MAIA Biotech|Earnings per share for the last twelve months Liminatus Pharma LLC (LIMN)|LVTX: Earnings per one share for the last 12 months|NextCure Inc - Net earnings per share for the last 12 months|Leap Therapeutics, Inc. (LPTX) - Net earnings per one share for the last twelve months|Intensity Therapeutics Inc - Net earnings per share (EPS TTM)|Net earnings per share for the last four quarters senseibio.com SNSE|Gritstone Bio (GRTS) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Kineta, Inc. (KA)|Net earnings per share for the last 12 months NEXI|TSBX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) VCNX|HARP: Earnings per one share for the last 12 months